Full Length Research Paper
References
|
Aboulmagd E, Alsultan AA, Al Mohammad HI, Al-Badry S, Hussein EM (2013). In vitro synergistic activity of amikacin combined with subinhibitory concentration of tigecycline against extended spectrum β-lactamase-producing Klebsiella pneumoniae. J. Microbiol. Antimicrob. 5(5):44-49. Crossref |
||||
| Al-Agamy MH, Shibl AM, Zaki SA, Tawfik AF (2011). Antimicrobial resistance pattern and prevalence of metallo-β-lactamases in Pseudomonas aeruginosa from Saudi Arabia. Afr. J. Microbiol. Res. 5(30):5528-5533. | ||||
|
Albur M, Noel A, Bowker K, MacGowan A (2012). Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 56(6):3441-3443. Crossref |
||||
|
AlSultan AA, Evans BA, Elsayed EA, Al-Thawadi SI, Al-Taher AY, Amyes S, Al-Dughaym AM, Hamouda A (2013). High frequency of carbapenem-resistant Acinetobacter baumannii in patients with diabetes mellitus in Saudi Arabia. J. Med. Microbiol. 62:885-888. Crossref |
||||
|
Bassetti M, Ginocchio F, Mikulska M, Taramasso L, Giacobbe DR (2011). Will new antimicrobials overcome resistance among Gram-negatives? Expert Rev. Anti. Infect. Ther. 9(10):909-922. Crossref |
||||
|
Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E (2013). Carbapenems. J. Chemother. 25(1):1-17. Crossref |
||||
|
Cai Y, Chai D, Wang R, Liang B, Bai N (2012). Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67(7):1607-1615. Crossref |
||||
|
Gould IM (2008). The epidemiology of antibiotic resistance. Int. J. Antimicrob. Agents 32(Suppl 1):S2-9. Crossref |
||||
|
Isturiz R (2008). Global resistance trends and the potential impact on empirical therapy. Int. J. Antimicrob. Agents 32 (Suppl 4):S201-206. Crossref |
||||
|
Johnson AP, Woodford N (2013). Global spread of antibiotic resistance: the example of New Delhi metallo-B-lactamase (NDM)-mediated carbapenem resistance. J. Med. Microbiol. 62(4):499-513. Crossref |
||||
|
Lee CR, Cho IH, Jeong BC, Lee SH (2013). Strategies to minimize antibiotic resistance. Int. J. Environ. Res. Public Health 10(9):4274-305. Crossref |
||||
|
Lee K, Youg D, Jeong SH, Chong Y (2011). Multidrug-resistant Acinetobacter spp: increasingly problematic nosocomial pathogens. Yonsei Med. J. 52(6):879-891. Crossref |
||||
|
Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, et al (2013). Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J. Infect. Dis. 208(7):1142-1151. Crossref |
||||
|
Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A 3rd, Forrest A, Bulitta JB, Tsuji BT (2010). Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30(12):1279-1291. Crossref |
||||
|
Lim TP, Tan TY, Lee W, Sasikala S, Tan TT, Hsu LY, Kwa AL (2011). In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One 6(4):e18485. Crossref |
||||
|
Livermore DM (2009). Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 64(Suppl 1):29-36. Crossref |
||||
|
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18:268-281. Crossref |
||||
|
Mammina C, Bonura C, Di Bernardo F, Aleo A, Fasciana T, Sodano C, Saporito MA, Verde MS, Tetamo R, Palma DM (2012). Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011. Euro Surveill. 17(33). pii:20248. Pubmed |
||||
|
Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, et al (2011). Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob. Agents Chemother. 55(2):593-599. Crossref |
||||
|
Memish ZA, Shibl AM, Kambal AM, Ohaly YA, Ishaq A, Livermore DM (2012). Antimicrobial resistance among non-fermenting Gram-negative bacteria in Saudi Arabia. J. Antimicrob. Chemother. 67(7):1701-1705. Crossref |
||||
|
Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (2011). Carbapenems: past, present and future. Antimicrob. Agents Chemother. 55(11):4943-4960. Crossref |
||||
|
Paterson DL, Doi Y (2007). A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin. Infect. Dis. 45(9):1179-1181. Crossref |
||||
|
Paterson DL, Lipman J (2007). Returning to the pre-antibiotic era in the critically ill: the XDR problem. Crit. Care Med. 35(7):1789-1791. Crossref |
||||
| Pillai SK, Moellering RC, Eliopoulos GM (2005). Antimicrobial combinations. In: Antibiotics in Laboratory Medicine, Ed. V. Lorian, 5th ed. Lippincott Williams & Wilkins. pp. 365-440. | ||||
|
Rahal JJ (2006). Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin. Infect. Dis. 1(43 Suppl 2):S95-99. Crossref |
||||
|
Rai J, Randhawa GK, Kaur M (2013). Recent advances in antibacterial drugs. Int. Appl. Basic Med. Res. 3(1):3-10. Crossref |
||||
|
Slama TG (2008). Gram-negative antibiotic resistance: there is a price to pay. Critical Care 12(Suppl 4):S4. Crossref |
||||
|
Urban C, Mariano N, Rahal JJ (2010). In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli. Antimicrob. Agents Chemother. 54(6):2732-2734. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
